News & Events


Overcoming Challenges in Neuro Degenerative Clinical Trials

Overcoming Challenges in Neuro Degenerative Clinical Trials
03 August 2018

The number of neuro degenerative clinical trials is increasing with Parkinson’s, Alzheimer’s, Lou Gehrig’s, MS, and other neuro degenerative diseases growing in prevalence, especially as the population ages. Costs to society, caregivers, and patients are high.

However, clinical trials involving neuro degenerative diseases pose a number of challenges. One is properly diagnosing patients. Approximately 30% of patients with diseases like Alzheimer’s and Parkinson’s are misdiagnosed, with pre-symptomatic patients often difficult to detect. Conversely, several diseases display Parkinsonian symptoms but aren't Parkinson’s.

Other issues may include data quality, protocol compliance and subject retention due to the lowered cognitive functioning of the subjects. A frequent need is to reduce the burden on patients and caregivers.

Linda Rawlings, VP of Neuro Degenerative Development at Synteract, sat down recently with reporter Moe Alsumidaie from Applied Clinical Trials to discuss innovations in this area. She noted some suggestions to address these challenges include looking for opportunities to simplify protocols, defining a smaller number of well-thought-out assessments, and enabling testing to be performed at home whenever possible.

What are other steps drug developers can take to overcome therapeutic challenges of these clinical trials? Read Linda’s full interview in “CROs Tackle Neurodegenerative Disease Studies” for more.


Contact Synteract

Tell us how to stay in touch with you: